<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01793610</url>
  </required_header>
  <id_info>
    <org_study_id>MP-12</org_study_id>
    <nct_id>NCT01793610</nct_id>
  </id_info>
  <brief_title>Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD</brief_title>
  <official_title>A Randomized, Double-Blind, Dose Response Phase 2 Pilot Study of Manualized MDMA-Assisted Psychotherapy in Subjects With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Multidisciplinary Association for Psychedelic Studies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Multidisciplinary Association for Psychedelic Studies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder that can develop&#xD;
      after a traumatic life experience that severely reduces quality of life. This Phase 2 pilot&#xD;
      study examined the safety and efficacy of MDMA-assisted psychotherapy in 23 subjects with&#xD;
      chronic, treatment-resistant posttraumatic stress disorder (PTSD). This study is part of a&#xD;
      global series of Phase 2 pilot clinical trials. This randomized, double-blind, dose response&#xD;
      study assessed two active doses of MDMA, 100 mg and 125 mg, to a comparator dose of MDMA (40&#xD;
      mg) during psychotherapy sessions. The initial dose was followed 1.5 to 2.5 hours later by an&#xD;
      optional supplemental dose of MDMA that was half the size of the first dose. MDMA was&#xD;
      administered in two experimental sessions lasting up to eight hours and scheduled three to&#xD;
      five weeks apart. Subjects were prepared for MDMA-assisted psychotherapy prior to the first&#xD;
      session in three preparatory sessions, and worked with the same pair of therapists throughout&#xD;
      the study. After each MDMA-assisted psychotherapy session, subjects had three integrative&#xD;
      sessions with their therapist team to process and understand their experience.&#xD;
&#xD;
      This study assessed the change in symptoms of PTSD, as measured by the Clinical Administered&#xD;
      PTSD Scale (CAPS) [Blake et al., 1995], as well as symptoms of depression, as measured by the&#xD;
      Beck Depression Inventory II (BDI-II) [Beck, A.T. and R.A, 1984; Beck, A.T., et al., 1996]&#xD;
      from baseline enrollment to one month after the second MDMA-assisted psychotherapy session&#xD;
      (primary endpoint).&#xD;
&#xD;
      Participants who received the comparator dose of MDMA (40 mg) were given the option to enroll&#xD;
      in Stage 2, where they underwent three open-label MDMA-assisted psychotherapy sessions with&#xD;
      an active dose of MDMA. People who received either of the active doses of MDMA in Stage 1 had&#xD;
      a third MDMA-assisted psychotherapy session with another active dose of MDMA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder that can develop&#xD;
      after a person experiences a traumatic event, such as sexual assault, war, or any other&#xD;
      life-threatening event. PTSD is a worldwide health problem that severely reduces a person's&#xD;
      quality of life and is associated with high rates of psychiatric and medical comorbidity,&#xD;
      disability, suffering, and suicide. At least a third of PTSD patients fail to respond to&#xD;
      established PTSD psychotherapies. A wider array of effective treatments for PTSD are needed.&#xD;
&#xD;
      3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy may be a potential treatment&#xD;
      option for PTSD. MDMA is a monoamine releaser that affects serotonin, norepinephrine, and&#xD;
      dopamine. MDMA is capable of inducing unique psychopharmacological effects such as decreased&#xD;
      feelings of fear, increased feelings of wellbeing, increased sociability and extroversion,&#xD;
      increased interpersonal trust, and an alert state of consciousness. In the U.S., MDMA was&#xD;
      used as an adjunct to psychotherapy by a considerable number of psychiatrists and therapists&#xD;
      before it was placed in Schedule I in 1985 as a result of non-medical use.&#xD;
&#xD;
      This Phase 2 pilot study is a randomized, double-blind, dose response study to examine the&#xD;
      safety and efficacy of MDMA-assisted psychotherapy in 23 subjects with chronic,&#xD;
      treatment-resistant PTSD of at least six months duration. This study is part of a global&#xD;
      series of Phase 2 pilot clinical trials. This study assessed two active doses of MDMA, active&#xD;
      dose 1 (100 mg) and active dose 2 (125 mg), to a comparator dose of MDMA (40 mg) during&#xD;
      psychotherapy sessions. The initial dose of MDMA was followed 1.5 to 2.5 hours later by an&#xD;
      optional supplemental dose of MDMA that was half the size of the first dose. MDMA was&#xD;
      administered orally in two experimental sessions lasting up to eight hours and scheduled&#xD;
      three to five weeks apart.&#xD;
&#xD;
      Subjects were prepared for MDMA-assisted psychotherapy in three preparatory sessions prior to&#xD;
      the first experimental session, and worked with the same pair of therapists throughout the&#xD;
      study. After each experimental session, three integrative sessions were scheduled with the&#xD;
      subject, including one integrative session the morning after the experimental session. During&#xD;
      integrative sessions, subjects processed and connected their thoughts and feelings about the&#xD;
      experience with their therapist team.&#xD;
&#xD;
      Subjects who received the comparator dose (40 mg) were given the option to enroll in Stage 2,&#xD;
      where they underwent three open-label MDMA-assisted psychotherapy sessions. 100 mg of MDMA&#xD;
      was administered in the first session and therapists determined whether to increase to 125 mg&#xD;
      of MDMA for the second and third experimental sessions. People who received 125 mg of MDMA&#xD;
      during the first two experimental sessions received the same dose during an open-label third&#xD;
      experimental session. People who received 100 mg of MDMA during the first two sessions were&#xD;
      able to choose, in consultation with their therapist, to either continue to receive 100 mg in&#xD;
      a third session or to increase their dose to 125 mg.&#xD;
&#xD;
      A blinded independent rater (IR) assessed the severity of PTSD symptoms at baseline, one&#xD;
      month after the second experimental session (the primary endpoint), two months after the&#xD;
      third open-label experimental session, and at equivalent points in Stage 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score at Baseline (ITT)</measure>
    <time_frame>Baseline Enrollment</time_frame>
    <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score at One Month Post 2nd Experimental Session (ITT)</measure>
    <time_frame>One month after 2nd experimental session (approximately 3 months post enrollment)</time_frame>
    <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score From Baseline to One Month Post 2nd Experimental Session (ITT)</measure>
    <time_frame>Baseline Enrollment to 1-Month Post 2nd Experimental Session</time_frame>
    <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory II (BDI-II) at Baseline (ITT)</measure>
    <time_frame>Baseline Enrollment</time_frame>
    <description>Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory II (BDI-II) at One Month Post 2nd Experimental Session (ITT)</measure>
    <time_frame>One month after 2nd experimental session (approximately 3 months post enrollment)</time_frame>
    <description>Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Beck Depression Inventory II (BDI-II) From Baseline to One Month Post 2nd Experimental Session (ITT)</measure>
    <time_frame>Baseline Enrollment to 1-Month Post 2nd Experimental Session</time_frame>
    <description>Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to One Month Post 2nd Experimental Session (ITT)</measure>
    <time_frame>Baseline Enrollment to 1-Month Post 2nd Experimental Session</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Comparator-dose (40 mg) MDMA and Psychotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive an initial dose of comparator-dose MDMA (40 mg) during each of the two experimental sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Dose 2 (100 mg) MDMA and Psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an initial dose of Active Dose 2 MDMA (100 mg) during each of the two experimental sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Dose 1 (125 mg) MDMA and Psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an initial dose of Active Dose 1 MDMA (125 mg) during each of two experimental sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparative-dose (40mg) MDMA</intervention_name>
    <description>An initial comparator-dose of 40 mg MDMA orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (20 mg MDMA).</description>
    <arm_group_label>Comparator-dose (40 mg) MDMA and Psychotherapy</arm_group_label>
    <other_name>3,4-methylenedioxymethamphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Dose 2 (100 mg) MDMA</intervention_name>
    <description>An initial dose of full-dose 100 mg MDMA orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (50 mg MDMA).</description>
    <arm_group_label>Active Dose 2 (100 mg) MDMA and Psychotherapy</arm_group_label>
    <other_name>3,4-methylenedioxymethamphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Dose 1 (125 mg) MDMA</intervention_name>
    <description>An initial dose of full-dose 125 mg MDMA orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (62.5 mg MDMA).</description>
    <arm_group_label>Active Dose 1 (125 mg) MDMA and Psychotherapy</arm_group_label>
    <other_name>3,4-methylenedioxymethamphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychotherapy</intervention_name>
    <description>Psychotherapy conducted throughout experimental sessions.</description>
    <arm_group_label>Active Dose 1 (125 mg) MDMA and Psychotherapy</arm_group_label>
    <arm_group_label>Active Dose 2 (100 mg) MDMA and Psychotherapy</arm_group_label>
    <arm_group_label>Comparator-dose (40 mg) MDMA and Psychotherapy</arm_group_label>
    <other_name>Manualized MDMA-assisted psychotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with chronic PTSD for six months or longer.&#xD;
&#xD;
          -  Have a CAPS score showing moderate to severe PTSD symptoms.&#xD;
&#xD;
          -  At least one unsuccessful attempt at treatment for PTSD either with talk therapy or&#xD;
             with drugs, or discontinuing treatment because of inability to tolerate psychotherapy&#xD;
             or drug therapy.&#xD;
&#xD;
          -  Are at least 18 years old.&#xD;
&#xD;
          -  Must be generally healthy.&#xD;
&#xD;
          -  Are willing to refrain from taking any psychiatric medications during the study&#xD;
             period.&#xD;
&#xD;
          -  Willing to follow restrictions and guidelines concerning consumption of food,&#xD;
             beverages or nicotine the night before and just prior to each MDMA session.&#xD;
&#xD;
          -  Willing to remain overnight at the study site.&#xD;
&#xD;
          -  Are willing to be driven home after experimental sessions either by a driver they&#xD;
             arrange, a taxi, or study personnel.&#xD;
&#xD;
          -  Are willing to be contacted via telephone by study personnel.&#xD;
&#xD;
          -  If of child-bearing age, must have a negative pregnancy and agree to use an effective&#xD;
             form of birth control.&#xD;
&#xD;
          -  Must provide a personal contact who is willing to be reached in case of emergency.&#xD;
&#xD;
          -  Agree to let the investigators know within 48 hours of any planned medical&#xD;
             interventions.&#xD;
&#xD;
          -  Are proficient in reading and speaking English.&#xD;
&#xD;
          -  Agree to have all psychotherapy sessions recorded.&#xD;
&#xD;
          -  Agree not to participate in any other interventional clinical trials during the course&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are pregnant or nursing, or if of child-bearing age and do not use an effective means&#xD;
             of birth control.&#xD;
&#xD;
          -  Weigh less than 48 kg.&#xD;
&#xD;
          -  Are abusing illegal drugs.&#xD;
&#xD;
          -  Are unable to give adequate informed consent.&#xD;
&#xD;
          -  Upon review of past and current drugs/medication, must not be on or have taken a&#xD;
             medication that is exclusionary.&#xD;
&#xD;
          -  Upon review of medical or psychiatric history, must not have any current or past&#xD;
             diagnosis that would be considered a risk to participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcela d'Otalora, MA, LPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Practice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Offices of Marcela d'Otalora</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995 Jan;8(1):75-90. Review.</citation>
    <PMID>7712061</PMID>
  </reference>
  <reference>
    <citation>Beck AT, Steer RA. Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol. 1984 Nov;40(6):1365-7.</citation>
    <PMID>6511949</PMID>
  </reference>
  <reference>
    <citation>Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996 Dec;67(3):588-97.</citation>
    <PMID>8991972</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <results_first_submitted>June 29, 2020</results_first_submitted>
  <results_first_submitted_qc>September 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <disposition_first_submitted>March 7, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 7, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 9, 2018</disposition_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDMA</keyword>
  <keyword>Posttraumatic stress disorder</keyword>
  <keyword>sleep</keyword>
  <keyword>Depression</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 15, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT01793610/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 26, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT01793610/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Candidates were recruited via Internet advertisements and referrals from mental health professionals. Potential participants were men and women 18 years or older. Inclusion criteria required PTSD for at least six months. The study was conducted at an outpatient clinic in Boulder, Colorado between October 2012 and February 2017.</recruitment_details>
      <pre_assignment_details>One participant was excluded for not meeting eligibility criteria after enrollment prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Comparator-dose MDMA (40 mg) and Psychotherapy</title>
          <description>Participants receive an initial dose of 40 mg of MDMA orally, with an optional supplemental dose of 20 mg MDMA 1.5 to 2.5 hours later.</description>
        </group>
        <group group_id="P2">
          <title>Active Dose 2 MDMA (100 mg) and Psychotherapy</title>
          <description>Participants receive an initial dose of 100 mg of MDMA orally, with an optional supplemental dose of 50 mg MDMA 1.5 to 2.5 hours later.</description>
        </group>
        <group group_id="P3">
          <title>Active Dose 1 MDMA (125 mg) and Psychotherapy</title>
          <description>Participants receive an initial dose of 125 mg of MDMA orally, with an optional supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat (ITT)</population>
      <group_list>
        <group group_id="B1">
          <title>Comparator-dose MDMA (40 mg) and Psychotherapy</title>
          <description>Participants receive an initial dose of 40 mg of MDMA orally, with an optional supplemental dose of 20 mg MDMA 1.5 to 2.5 hours later.</description>
        </group>
        <group group_id="B2">
          <title>Active Dose 2 MDMA (100 mg) and Psychotherapy</title>
          <description>Participants receive an initial dose of 100 mg of MDMA orally, with an optional supplemental dose of 50 mg MDMA 1.5 to 2.5 hours later.</description>
        </group>
        <group group_id="B3">
          <title>Active Dose 1 MDMA (125 mg) and Psychotherapy</title>
          <description>Participants receive an initial dose of 125 mg of MDMA orally, with an optional supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="11.7"/>
                    <measurement group_id="B2" value="39.6" spread="9.8"/>
                    <measurement group_id="B3" value="44.6" spread="15.4"/>
                    <measurement group_id="B4" value="42" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score at Baseline (ITT)</title>
        <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.</description>
        <time_frame>Baseline Enrollment</time_frame>
        <population>Intent-to-Treat set (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Comparator-dose MDMA (40 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 40 mg of MDMA orally, with an optional supplemental dose of 20 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O2">
            <title>Active Dose 2 MDMA (100 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 100 mg of MDMA orally, with an optional supplemental dose of 50 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O3">
            <title>Active Dose 1 MDMA (125 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 125 mg of MDMA orally, with an optional supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score at Baseline (ITT)</title>
          <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.</description>
          <population>Intent-to-Treat set (ITT)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8" spread="8.04"/>
                    <measurement group_id="O2" value="94.4" spread="20.17"/>
                    <measurement group_id="O3" value="93.5" spread="20.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score at One Month Post 2nd Experimental Session (ITT)</title>
        <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.</description>
        <time_frame>One month after 2nd experimental session (approximately 3 months post enrollment)</time_frame>
        <population>Intent-to-Treat set (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Comparator-dose MDMA (40 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 40 mg of MDMA orally, with an optional supplemental dose of 20 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O2">
            <title>Active Dose 2 MDMA (100 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 100 mg of MDMA orally, with an optional supplemental dose of 50 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O3">
            <title>Active Dose 1 MDMA (125 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 125 mg of MDMA orally, with an optional supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score at One Month Post 2nd Experimental Session (ITT)</title>
          <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.</description>
          <population>Intent-to-Treat set (ITT)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3" spread="24.49"/>
                    <measurement group_id="O2" value="70.0" spread="28.19"/>
                    <measurement group_id="O3" value="64.3" spread="33.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score From Baseline to One Month Post 2nd Experimental Session (ITT)</title>
        <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.</description>
        <time_frame>Baseline Enrollment to 1-Month Post 2nd Experimental Session</time_frame>
        <population>Intent-to-Treat set (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Comparator-dose (40 mg) MDMA and Psychotherapy</title>
            <description>Participants receive an initial dose of 40 mg of MDMA orally, with an optional supplemental dose of 20 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O2">
            <title>Active Dose 2 (100 mg) MDMA and Psychotherapy</title>
            <description>Participants receive an initial dose of 100 mg of MDMA orally, with an optional supplemental dose of 50 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O3">
            <title>Active Dose 1 (125 mg) MDMA and Psychotherapy</title>
            <description>Participants receive an initial dose of 125 mg of MDMA orally, with an optional supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score From Baseline to One Month Post 2nd Experimental Session (ITT)</title>
          <description>The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.</description>
          <population>Intent-to-Treat set (ITT)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="21.21"/>
                    <measurement group_id="O2" value="-24.4" spread="24.22"/>
                    <measurement group_id="O3" value="-26.3" spread="29.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory II (BDI-II) at Baseline (ITT)</title>
        <description>Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.</description>
        <time_frame>Baseline Enrollment</time_frame>
        <population>Intent-to-Treat set (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Comparator-dose MDMA (40 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 40 mg of MDMA orally, with an optional supplemental dose of 20 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O2">
            <title>Active Dose 2 MDMA (100 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 100 mg of MDMA orally, with an optional supplemental dose of 50 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O3">
            <title>Active Dose 1 MDMA (125 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 125 mg of MDMA orally, with an optional supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory II (BDI-II) at Baseline (ITT)</title>
          <description>Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.</description>
          <population>Intent-to-Treat set (ITT)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="6.24"/>
                    <measurement group_id="O2" value="28.2" spread="13.62"/>
                    <measurement group_id="O3" value="29.3" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beck Depression Inventory II (BDI-II) at One Month Post 2nd Experimental Session (ITT)</title>
        <description>Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.</description>
        <time_frame>One month after 2nd experimental session (approximately 3 months post enrollment)</time_frame>
        <population>Intent-to-Treat set (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Comparator-dose MDMA (40 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 40 mg of MDMA orally, with an optional supplemental dose of 20 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O2">
            <title>Active Dose 2 MDMA (100 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 100 mg of MDMA orally, with an optional supplemental dose of 50 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O3">
            <title>Active Dose 1 MDMA (125 mg) and Psychotherapy</title>
            <description>Participants receive an initial dose of 125 mg of MDMA orally, with an optional supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
        </group_list>
        <measure>
          <title>Beck Depression Inventory II (BDI-II) at One Month Post 2nd Experimental Session (ITT)</title>
          <description>Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.</description>
          <population>Intent-to-Treat set (ITT)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="6.31"/>
                    <measurement group_id="O2" value="18.3" spread="16.23"/>
                    <measurement group_id="O3" value="17.3" spread="16.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Beck Depression Inventory II (BDI-II) From Baseline to One Month Post 2nd Experimental Session (ITT)</title>
        <description>Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.</description>
        <time_frame>Baseline Enrollment to 1-Month Post 2nd Experimental Session</time_frame>
        <population>Intent-to-Treat set (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Comparator-dose (40 mg) MDMA and Psychotherapy</title>
            <description>Participants receive an initial dose of 40 mg of MDMA orally, with an optional supplemental dose of 20 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O2">
            <title>Active Dose 2 (100 mg) MDMA and Psychotherapy</title>
            <description>Participants receive an initial dose of 100 mg of MDMA orally, with an optional supplemental dose of 50 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O3">
            <title>Active Dose 1 (125 mg) MDMA and Psychotherapy</title>
            <description>Participants receive an initial dose of 125 mg of MDMA orally, with an optional supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beck Depression Inventory II (BDI-II) From Baseline to One Month Post 2nd Experimental Session (ITT)</title>
          <description>Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.</description>
          <population>Intent-to-Treat set (ITT)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="7.79"/>
                    <measurement group_id="O2" value="-9.9" spread="13.26"/>
                    <measurement group_id="O3" value="-11.0" spread="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to One Month Post 2nd Experimental Session (ITT)</title>
        <description>The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.</description>
        <time_frame>Baseline Enrollment to 1-Month Post 2nd Experimental Session</time_frame>
        <population>Intent-to-Treat set (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Comparator-dose (40 mg) MDMA and Psychotherapy</title>
            <description>Participants receive an initial dose of 40 mg of MDMA orally, with an optional supplemental dose of 20 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O2">
            <title>Active Dose 2 (100 mg) MDMA and Psychotherapy</title>
            <description>Participants receive an initial dose of 100 mg of MDMA orally, with an optional supplemental dose of 50 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
          <group group_id="O3">
            <title>Active Dose 1 (125 mg) MDMA and Psychotherapy</title>
            <description>Participants receive an initial dose of 125 mg of MDMA orally, with an optional supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to One Month Post 2nd Experimental Session (ITT)</title>
          <description>The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.</description>
          <population>Intent-to-Treat set (ITT)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="2.48"/>
                    <measurement group_id="O2" value="-3.56" spread="6.19"/>
                    <measurement group_id="O3" value="-1.92" spread="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During and Seven Days Following Blinded Experimental Sessions 1 and 2</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Comparator-dose MDMA (40 mg) and Psychotherapy</title>
          <description>Participants receive an initial dose of 40 mg of MDMA orally, with an optional supplemental dose of 20 mg MDMA 1.5 to 2.5 hours later.</description>
        </group>
        <group group_id="E2">
          <title>Active Dose 2 MDMA (100 mg) and Psychotherapy</title>
          <description>Participants receive an initial dose of 100 mg of MDMA orally, with an optional supplemental dose of 50 mg MDMA 1.5 to 2.5 hours later.</description>
        </group>
        <group group_id="E3">
          <title>Active Dose 1 MDMA (125 mg) and Psychotherapy</title>
          <description>Participants receive an initial dose of 125 mg of MDMA orally, with an optional supplemental dose of 62.5 mg MDMA 1.5 to 2.5 hours later.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ruptured ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Difficulty concentrating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Increased irritability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lack of appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Need more sleep</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ruminations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Jaw clenching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Muscle tension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" events="13" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E3" events="17" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Low mood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julie B. Wang, MPH, PhD/ Senior Clinical Data Scientist</name_or_title>
      <organization>Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corp.</organization>
      <phone>(831) 429-6362</phone>
      <email>juliewang@mapsbcorp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

